Every 10-Q that GREEN THUMB INDUS SUB VTG (GTBIF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GTBIF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GTBIF filings page.
Green Thumb Industries Inc. generated revenue of $306,683 thousand for the quarter and $606,873 thousand for the six months ended June 30 2026, up 5% and 6% from the prior‑year periods. Net income attributable to the company was $4,878 thousand for the quarter and $20,275 thousand year‑to‑date, or $0.02 and $0.09 per diluted share.
Gross margin was 45% for the quarter, down from 50%, as cost of goods sold rose 15%, including $15,750 thousand of licensing fees to RYM, along with Minnesota adult‑use ramp‑up and price compression in certain markets. The effective tax rate was 78.5% for the quarter and 76.64% year‑to‑date under Section 280E, while medical cannabis was reclassified to Schedule III in April 2026 and tax guidance is pending.
Cash and cash equivalents were $283,586 thousand and total assets $2,815,413 thousand as of June 30 2026. Operating cash flow of $104,810 thousand funded $39,077 thousand of capital expenditures and $81,559 thousand of share repurchases, including 13,438,787 Subordinate Voting Shares. The company consolidated eight additional retail dispensary licenses, recognized a $17,000 thousand arbitration award, and had $183,750 thousand of principal outstanding on its $200,000 thousand syndicated credit facility.
Green Thumb Industries Inc. reported solid results for the quarter ended March 31, 2026. Revenue reached $300,190 thousand, up 7% year over year, while net income attributable to the company nearly doubled to $15,397 thousand, or $0.07 per diluted share.
Gross profit held steady at $143,645 thousand, though gross margin slipped to 48% as licensing fees and price pressure offset growth in newer and existing markets. Operating income was $40,734 thousand, with total other income boosted by a $17,000 thousand arbitration settlement and earnings from an equity-method investee.
Operating cash flow was strong at $75,799 thousand, helping lift cash and restricted cash to $346,212 thousand. The company expanded its syndicated credit facility to $200,000 thousand of capacity and ended the quarter with working capital of $479,695 thousand. A subsequent U.S. Department of Justice order moved state-licensed medical marijuana to Schedule III, which would remove section 280E tax constraints for that portion of the business.
Green Thumb Industries (GTBIF) reported Q3 2025 results. Revenue reached $291.4 million, up slightly year over year. Gross profit was $144.0 million as cost of goods sold increased, and SG&A totaled $107.3 million. Net income attributable to the company was $23.3 million, or $0.10 per diluted share. Other income included a $41.6 million gain from divesting certain brand intellectual property with concurrent licensing back.
Year to date, revenue was $864.2 million and operating cash flow was $204.8 million. Cash and cash equivalents were $226.2 million, with $9.2 million in restricted cash tied to an appeal bond. The company ended the quarter with $247.4 million of notes payable, including a $150 million credit facility (SOFR + 500 bps) and was in covenant compliance. During the nine months, $24.8 million of Subordinate Voting Shares were repurchased; a new program authorizes repurchases of up to 10,364,640 shares at an aggregate cost of up to $50.0 million. The effective tax rate remained elevated under IRC Section 280E.